摘要
目的:探讨瑞格列奈联合阿卡波糖治疗2型糖尿病的效果。方法:选取86例2型糖尿病患者,随机分为对照组和观察组各43例,对照组给予瑞格列奈治疗,观察组在对照组的基础上加用阿卡波糖,均连续治疗4周,比较2组临床治疗效果、主要生理指标变化及安全性。结果:治疗后,对照组临床总有效率76.7%,低于观察组的97.7%(P<0.05);观察组空腹血糖、餐后2 h血糖及糖化血红蛋白改善程度均明显优于对照组(P<0.01);对照组不良反应总发生率16.3%,观察组不良反应发生率为11.6%,差异无统计学意义(P>0.05)。结论:瑞格列奈联合阿卡波糖治疗2型糖尿病可显著改善患者的主要生理指标参数,提高临床治疗效果,且安全性较好。
Objective:To explore the effects of repaglinide combined with acarbose in the treatment of type 2 diabetes mellitus. Methods:Eighty-six patients with type 2 diabetes were randomly divided into the control group and observation group,43 cases in each group. The control group and observation group were treated with repaglinide and repaglinide combined with acarbose for 4 weeks, respectively. The clinical effects,changes of pysiological idexes and safety between two groups were compared. Results:After treatment, the clinical total effective rates in control group and observation group were 76. 7% and 97. 7%,respectively,the difference of which was statistically significant(P 〈0. 05). The improvement of fasting blood glucose,2 h postprandial blood glucose and glycosylated hemoglobin in observation group were significantly better than those in control group(P〈0. 01). The incidence of the total adverse reaction rates in control group and observation group were 16. 3% and 11. 6%,respectively,the difference of which was not statistically significant(P〉0. 05). Conclusions:The treatment of type 2 diabetes with repaglinide combined with acarbose can significantly improve the main physiological indexes and clinical treatment effects,and the safety of which is good.
出处
《蚌埠医学院学报》
CAS
2015年第7期869-870,873,共3页
Journal of Bengbu Medical College